These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.

Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.

The American Association for Cancer Research has released its annual Cancer Progress Report, highlighting the recent progress in cancer research. Keith Flaherty, M.D., chair of the AACR Cancer ...

In this study, researchers evaluated patterns of practice-reported screening for pain and depression as well as patient-reported receipt of assistance for these conditions.

Researchers analyzed the domain coverage and clinical application of screening tools used to assess palliative care needs in oncology.

An estimated 22.0 percent of CRC cases were potentially related to H. pylori exposure under pooled risk-attribution model.

In the MATCH trial, researchers assessed mindfulness-based cancer recovery and tai chi/qigong for individuals with cancer who were suffering from distress after treatment.

A presentation at ONS Bridge 2026 highlights the germline and somatic genomic factors associated with colorectal cancer, emphasizing how nurses can utilize genomics to inform risk assessment and ...

A presentation at ONS Bridge 2026 outlines the 4Ms framework for providing age-friendly care to older patients with cancer.

These results highlight the need for clinicians to investigate potential high-grade lymphoid malignancies in cases of refractory CAD.

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

An implementation research protocol evaluates health system capacity for delivering integrated HPV vaccination and cervical cancer screening services.